White Paper

Qorvo Biotechnologies Omnia Instrument Testing System

Source: Qorvo
wp

This white paper describes the Qorvo Biotechnologies Omnia testing system using bulk acoustic wave (BAW) sensor technology and performance data generated in a recent study conducted by the NIH as part of the RADx initiative for SARS-CoV-2 antigen testing. The Qorvo Omnia SARS-CoV-2 Antigen test was granted EUA authorization for the qualitative detection of SARS-CoV-2 nucleocapsid viral antigens from direct anterior nasal swab specimens without transport media from symptomatic individuals who are suspected of COVID-19 by their healthcare provider within the first six days of symptom onset. The EUA is limited to laboratories certified under CLIA to perform moderate or high-complexity testing. For more information on this topic, download the full white paper.

VIEW THE WHITE PAPER!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of RF Globalnet? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: